Boston Pharmaceuticals Widens Opportunities With New GSK Assets
Company In-Licenses Oncology, Neurology Drugs
In an interview, CEO Rob Armstrong said the company has created “a lot optionality” for how it can develop the programs it takes on from the big pharma’s portfolio management.
